APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-Obesity Prescription Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Anti-Obesity Prescription Drugs Market Outlook and Growth Opportunities 2026

21 December 2025190 pages

Choose your research edition.

Industry ResearchAnti-Obesity Prescription Drugs Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-Obesity Prescription Drugs Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Anti-Obesity Prescription Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-Obesity Prescription Drugs Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-Obesity Prescription Drugs Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Anti-Obesity Prescription Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Anti-Obesity Prescription Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Anti-Obesity Prescription Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anti-Obesity Prescription Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Anti-Obesity Prescription Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Anti-Obesity Prescription Drugs market include Novo Nordisk A/s, Glaxosmithkline, Vivus, Orexigen Therapeutics, F Hoffmann La Roche Ltd, Boehringer Ingelheim, Arena Pharmaceuticals and Alizyme, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Anti-Obesity Prescription Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anti-Obesity Prescription Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anti-Obesity Prescription Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Anti-Obesity Prescription Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Anti-Obesity Prescription Drugs Segment by Company

Novo Nordisk A/s

Glaxosmithkline

Vivus

Orexigen Therapeutics

F Hoffmann La Roche Ltd

Boehringer Ingelheim

Arena Pharmaceuticals

Alizyme

Anti-Obesity Prescription Drugs Segment by Type

Pediatric

Adult

Anti-Obesity Prescription Drugs Segment by Application

Hospitals Pharmacies

E-commerce

Retail Pharmacies

Anti-Obesity Prescription Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Anti-Obesity Prescription Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Anti-Obesity Prescription Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Anti-Obesity Prescription Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Anti-Obesity Prescription Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Obesity Prescription Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-Obesity Prescription Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Obesity Prescription Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Anti-Obesity Prescription Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anti-Obesity Prescription Drugs industry.

Chapter 3: Detailed analysis of Anti-Obesity Prescription Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Anti-Obesity Prescription Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Anti-Obesity Prescription Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Anti-Obesity Prescription Drugs Industry Trends Table 2. Anti-Obesity Prescription Drugs Industry Drivers Table 3. Anti-Obesity Prescription Drugs Industry Opportunities and Challenges Table 4. Anti-Obesity Prescription Drugs Industry Restraints Table 5. Global Anti-Obesity Prescription Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Anti-Obesity Prescription Drugs Revenue Share by Company (2021-2026) Table 7. Global Anti-Obesity Prescription Drugs Sales Volume by Company (k units) & (2021-2026) Table 8. Global Anti-Obesity Prescription Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Anti-Obesity Prescription Drugs Average Price (US$/unit) of Company (2021-2026) Table 10. Global Anti-Obesity Prescription Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Anti-Obesity Prescription Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Anti-Obesity Prescription Drugs Company, Product Type & Application Table 13. Global Anti-Obesity Prescription Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Anti-Obesity Prescription Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Pediatric Table 18. Significant Companies of Adult Table 19. Global Anti-Obesity Prescription Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Anti-Obesity Prescription Drugs Sales Volume by Type (2021-2026) & (k units) Table 21. Global Anti-Obesity Prescription Drugs Sales Volume by Type (2027-2032) & (k units) Table 22. Global Anti-Obesity Prescription Drugs Sales Volume Share by Type (2021-2026) Table 23. Global Anti-Obesity Prescription Drugs Sales Volume Share by Type (2027-2032) Table 24. Global Anti-Obesity Prescription Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Anti-Obesity Prescription Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Anti-Obesity Prescription Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Anti-Obesity Prescription Drugs Sales Value Share by Type (2021-2026) Table 28. Global Anti-Obesity Prescription Drugs Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospitals Pharmacies Table 30. Significant Companies of E-commerce Table 31. Significant Companies of Retail Pharmacies Table 32. Global Anti-Obesity Prescription Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Anti-Obesity Prescription Drugs Sales Volume by Application (2021-2026) & (k units) Table 34. Global Anti-Obesity Prescription Drugs Sales Volume by Application (2027-2032) & (k units) Table 35. Global Anti-Obesity Prescription Drugs Sales Volume Share by Application (2021-2026) Table 36. Global Anti-Obesity Prescription Drugs Sales Volume Share by Application (2027-2032) Table 37. Global Anti-Obesity Prescription Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Anti-Obesity Prescription Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Anti-Obesity Prescription Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Anti-Obesity Prescription Drugs Sales Value Share by Application (2021-2026) Table 41. Global Anti-Obesity Prescription Drugs Sales Value Share by Application (2027-2032) Table 42. Global Anti-Obesity Prescription Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Anti-Obesity Prescription Drugs Sales by Region (2021-2026) & (k units) Table 44. Global Anti-Obesity Prescription Drugs Sales Market Share by Region (2021-2026) Table 45. Global Anti-Obesity Prescription Drugs Sales by Region (2027-2032) & (k units) Table 46. Global Anti-Obesity Prescription Drugs Sales Market Share by Region (2027-2032) Table 47. Global Anti-Obesity Prescription Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Anti-Obesity Prescription Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Anti-Obesity Prescription Drugs Sales Value Share by Region (2021-2026) Table 50. Global Anti-Obesity Prescription Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Anti-Obesity Prescription Drugs Sales Value Share by Region (2027-2032) Table 52. Global Anti-Obesity Prescription Drugs Market Average Price (US$/unit) by Region (2021-2026) Table 53. Global Anti-Obesity Prescription Drugs Market Average Price (US$/unit) by Region (2027-2032) Table 54. Global Anti-Obesity Prescription Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Global Anti-Obesity Prescription Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Anti-Obesity Prescription Drugs Sales by Country (2021-2026) & (k units) Table 57. Global Anti-Obesity Prescription Drugs Sales Market Share by Country (2021-2026) Table 58. Global Anti-Obesity Prescription Drugs Sales by Country (2027-2032) & (k units) Table 59. Global Anti-Obesity Prescription Drugs Sales Market Share by Country (2027-2032) Table 60. Global Anti-Obesity Prescription Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Anti-Obesity Prescription Drugs Sales Value Market Share by Country (2021-2026) Table 62. Global Anti-Obesity Prescription Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Anti-Obesity Prescription Drugs Sales Value Market Share by Country (2027-2032) Table 64. Novo Nordisk A/s Company Information Table 65. Novo Nordisk A/s Business Overview Table 66. Novo Nordisk A/s Anti-Obesity Prescription Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 67. Novo Nordisk A/s Anti-Obesity Prescription Drugs Product Portfolio Table 68. Novo Nordisk A/s Recent Development Table 69. Glaxosmithkline Company Information Table 70. Glaxosmithkline Business Overview Table 71. Glaxosmithkline Anti-Obesity Prescription Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Glaxosmithkline Anti-Obesity Prescription Drugs Product Portfolio Table 73. Glaxosmithkline Recent Development Table 74. Vivus Company Information Table 75. Vivus Business Overview Table 76. Vivus Anti-Obesity Prescription Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Vivus Anti-Obesity Prescription Drugs Product Portfolio Table 78. Vivus Recent Development Table 79. Orexigen Therapeutics Company Information Table 80. Orexigen Therapeutics Business Overview Table 81. Orexigen Therapeutics Anti-Obesity Prescription Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Orexigen Therapeutics Anti-Obesity Prescription Drugs Product Portfolio Table 83. Orexigen Therapeutics Recent Development Table 84. F Hoffmann La Roche Ltd Company Information Table 85. F Hoffmann La Roche Ltd Business Overview Table 86. F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Product Portfolio Table 88. F Hoffmann La Roche Ltd Recent Development Table 89. Boehringer Ingelheim Company Information Table 90. Boehringer Ingelheim Business Overview Table 91. Boehringer Ingelheim Anti-Obesity Prescription Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Boehringer Ingelheim Anti-Obesity Prescription Drugs Product Portfolio Table 93. Boehringer Ingelheim Recent Development Table 94. Arena Pharmaceuticals Company Information Table 95. Arena Pharmaceuticals Business Overview Table 96. Arena Pharmaceuticals Anti-Obesity Prescription Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Arena Pharmaceuticals Anti-Obesity Prescription Drugs Product Portfolio Table 98. Arena Pharmaceuticals Recent Development Table 99. Alizyme Company Information Table 100. Alizyme Business Overview Table 101. Alizyme Anti-Obesity Prescription Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Alizyme Anti-Obesity Prescription Drugs Product Portfolio Table 103. Alizyme Recent Development Table 104. Key Raw Materials Table 105. Raw Materials Key Suppliers Table 106. Anti-Obesity Prescription Drugs Distributors List Table 107. Anti-Obesity Prescription Drugs Customers List Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources Table 111. Primary Sources List of Figures Figure 1. Anti-Obesity Prescription Drugs Product Image Figure 2. Global Anti-Obesity Prescription Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-Obesity Prescription Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Anti-Obesity Prescription Drugs Sales (2021-2032) & (k units) Figure 5. Global Anti-Obesity Prescription Drugs Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Anti-Obesity Prescription Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Pediatric Image Figure 10. Adult Image Figure 11. Global Anti-Obesity Prescription Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Anti-Obesity Prescription Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Anti-Obesity Prescription Drugs Sales Volume Share by Type (2021-2032) Figure 14. Global Anti-Obesity Prescription Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Anti-Obesity Prescription Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Anti-Obesity Prescription Drugs Sales Value Share by Type (2021-2032) Figure 17. Hospitals Pharmacies Image Figure 18. E-commerce Image Figure 19. Retail Pharmacies Image Figure 20. Global Anti-Obesity Prescription Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Anti-Obesity Prescription Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Anti-Obesity Prescription Drugs Sales Volume Share by Application (2021-2032) Figure 23. Global Anti-Obesity Prescription Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Anti-Obesity Prescription Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Anti-Obesity Prescription Drugs Sales Value Share by Application (2021-2032) Figure 26. Global Anti-Obesity Prescription Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 27. Global Anti-Obesity Prescription Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Anti-Obesity Prescription Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Anti-Obesity Prescription Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Anti-Obesity Prescription Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. North America Anti-Obesity Prescription Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Anti-Obesity Prescription Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Anti-Obesity Prescription Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Anti-Obesity Prescription Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Anti-Obesity Prescription Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Anti-Obesity Prescription Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. South America Anti-Obesity Prescription Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Anti-Obesity Prescription Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Anti-Obesity Prescription Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Anti-Obesity Prescription Drugs Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Anti-Obesity Prescription Drugs Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Pediatric
  • Adult
Applications
  • Hospitals Pharmacies
  • E-commerce
  • Retail Pharmacies
Companies covered
  • Novo Nordisk A/s
  • Glaxosmithkline
  • Vivus
  • Orexigen Therapeutics
  • F Hoffmann La Roche Ltd
  • Boehringer Ingelheim
  • Arena Pharmaceuticals
  • Alizyme

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Anti-Obesity Prescription Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Anti-Obesity Prescription Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Anti-Obesity Prescription Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Anti-Obesity Prescription Drugs Market Dynamics
  1. 2.1 Anti-Obesity Prescription Drugs Industry Trends
  2. 2.2 Anti-Obesity Prescription Drugs Industry Drivers
  3. 2.3 Anti-Obesity Prescription Drugs Industry Opportunities and Challenges
  4. 2.4 Anti-Obesity Prescription Drugs Industry Restraints
3 Anti-Obesity Prescription Drugs Market by Company
  1. 3.1 Global Anti-Obesity Prescription Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Anti-Obesity Prescription Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Anti-Obesity Prescription Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Anti-Obesity Prescription Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Anti-Obesity Prescription Drugs Company Ranking (2024-2026)
  6. 3.6 Global Anti-Obesity Prescription Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Anti-Obesity Prescription Drugs Company Product Type and Application
  8. 3.8 Global Anti-Obesity Prescription Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Anti-Obesity Prescription Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Anti-Obesity Prescription Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Anti-Obesity Prescription Drugs Market by Type
  1. 4.1 Anti-Obesity Prescription Drugs Type Introduction
  2. 4.1.1 Pediatric
  3. 4.1.2 Adult
  4. 4.2 Global Anti-Obesity Prescription Drugs Sales Volume by Type
  5. 4.2.1 Global Anti-Obesity Prescription Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Anti-Obesity Prescription Drugs Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Anti-Obesity Prescription Drugs Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Anti-Obesity Prescription Drugs Sales Value by Type
  9. 4.3.1 Global Anti-Obesity Prescription Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Anti-Obesity Prescription Drugs Sales Value by Type (2021-2032)
  11. 4.3.3 Global Anti-Obesity Prescription Drugs Sales Value Share by Type (2021-2032)
5 Anti-Obesity Prescription Drugs Market by Application
  1. 5.1 Anti-Obesity Prescription Drugs Application Introduction
  2. 5.1.1 Hospitals Pharmacies
  3. 5.1.2 E-commerce
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Anti-Obesity Prescription Drugs Sales Volume by Application
  6. 5.2.1 Global Anti-Obesity Prescription Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Anti-Obesity Prescription Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Anti-Obesity Prescription Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Anti-Obesity Prescription Drugs Sales Value by Application
  10. 5.3.1 Global Anti-Obesity Prescription Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Anti-Obesity Prescription Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Anti-Obesity Prescription Drugs Sales Value Share by Application (2021-2032)
6 Anti-Obesity Prescription Drugs Regional Sales and Value Analysis
  1. 6.1 Global Anti-Obesity Prescription Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anti-Obesity Prescription Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Anti-Obesity Prescription Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Anti-Obesity Prescription Drugs Sales by Region (2027-2032)
  5. 6.3 Global Anti-Obesity Prescription Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Anti-Obesity Prescription Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Anti-Obesity Prescription Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Anti-Obesity Prescription Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Anti-Obesity Prescription Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Anti-Obesity Prescription Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Anti-Obesity Prescription Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Anti-Obesity Prescription Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Anti-Obesity Prescription Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Anti-Obesity Prescription Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Anti-Obesity Prescription Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Anti-Obesity Prescription Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Anti-Obesity Prescription Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Anti-Obesity Prescription Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Anti-Obesity Prescription Drugs Sales Value Share by Country, 2025 VS 2032
7 Anti-Obesity Prescription Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Anti-Obesity Prescription Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Anti-Obesity Prescription Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Anti-Obesity Prescription Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Anti-Obesity Prescription Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Anti-Obesity Prescription Drugs Sales by Country (2027-2032)
  6. 7.4 Global Anti-Obesity Prescription Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Anti-Obesity Prescription Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Anti-Obesity Prescription Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Anti-Obesity Prescription Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Anti-Obesity Prescription Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Anti-Obesity Prescription Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novo Nordisk A/s
  2. 8.1.1 Novo Nordisk A/s Company Information
  3. 8.1.2 Novo Nordisk A/s Business Overview
  4. 8.1.3 Novo Nordisk A/s Anti-Obesity Prescription Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Novo Nordisk A/s Anti-Obesity Prescription Drugs Product Portfolio
  6. 8.1.5 Novo Nordisk A/s Recent Developments
  7. 8.2 Glaxosmithkline
  8. 8.2.1 Glaxosmithkline Company Information
  9. 8.2.2 Glaxosmithkline Business Overview
  10. 8.2.3 Glaxosmithkline Anti-Obesity Prescription Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Glaxosmithkline Anti-Obesity Prescription Drugs Product Portfolio
  12. 8.2.5 Glaxosmithkline Recent Developments
  13. 8.3 Vivus
  14. 8.3.1 Vivus Company Information
  15. 8.3.2 Vivus Business Overview
  16. 8.3.3 Vivus Anti-Obesity Prescription Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Vivus Anti-Obesity Prescription Drugs Product Portfolio
  18. 8.3.5 Vivus Recent Developments
  19. 8.4 Orexigen Therapeutics
  20. 8.4.1 Orexigen Therapeutics Company Information
  21. 8.4.2 Orexigen Therapeutics Business Overview
  22. 8.4.3 Orexigen Therapeutics Anti-Obesity Prescription Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Orexigen Therapeutics Anti-Obesity Prescription Drugs Product Portfolio
  24. 8.4.5 Orexigen Therapeutics Recent Developments
  25. 8.5 F Hoffmann La Roche Ltd
  26. 8.5.1 F Hoffmann La Roche Ltd Company Information
  27. 8.5.2 F Hoffmann La Roche Ltd Business Overview
  28. 8.5.3 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Product Portfolio
  30. 8.5.5 F Hoffmann La Roche Ltd Recent Developments
  31. 8.6 Boehringer Ingelheim
  32. 8.6.1 Boehringer Ingelheim Company Information
  33. 8.6.2 Boehringer Ingelheim Business Overview
  34. 8.6.3 Boehringer Ingelheim Anti-Obesity Prescription Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Boehringer Ingelheim Anti-Obesity Prescription Drugs Product Portfolio
  36. 8.6.5 Boehringer Ingelheim Recent Developments
  37. 8.7 Arena Pharmaceuticals
  38. 8.7.1 Arena Pharmaceuticals Company Information
  39. 8.7.2 Arena Pharmaceuticals Business Overview
  40. 8.7.3 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Product Portfolio
  42. 8.7.5 Arena Pharmaceuticals Recent Developments
  43. 8.8 Alizyme
  44. 8.8.1 Alizyme Company Information
  45. 8.8.2 Alizyme Business Overview
  46. 8.8.3 Alizyme Anti-Obesity Prescription Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Alizyme Anti-Obesity Prescription Drugs Product Portfolio
  48. 8.8.5 Alizyme Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Anti-Obesity Prescription Drugs Value Chain Analysis
  2. 9.1.1 Anti-Obesity Prescription Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Anti-Obesity Prescription Drugs Sales Mode & Process
  6. 9.2 Anti-Obesity Prescription Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Anti-Obesity Prescription Drugs Distributors
  9. 9.2.3 Anti-Obesity Prescription Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst